New drug combo aims to fight tough lung cancer

NCT ID NCT07200154

Not yet recruiting Disease control Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding the immunotherapy drug adebrelimab to standard chemoradiotherapy can help people with limited-stage small-cell lung cancer. About 30 participants will receive the combination, followed by maintenance adebrelimab for up to 2 years. The study will look at how long the cancer stays under control and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adebrelimab (an immunotherapy drug) combined with chemotherapy and radiation therapy
What this could lead to: If successful, this could point toward a new treatment option for limited-stage small-cell lung cancer, potentially improving how long patients live without the cancer growing.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug combination may cause serious side effects, and it is not yet known if it works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONCURRENT CHEMORADIATION THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONCURRENT CHEMORADIATION THERAPY LIMITED-STAGE SMALL-CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking University Cancer Hospital and Institute

Beijing, Beijing Municipality, 100142, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.